SNY News and Press, Sanofi From 05/15/24

2024-05-15 12:22:59 ET More on Takeda Pharmaceutical Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript Takeda Pharmaceutical Company Limited 2023 Q4 - Results - Earnings Call Presentation Takeda Pharmaceutical: Eohilia's FDA Approv...

2024-05-15 08:45:36 ET Summary Pfizer has been a losing investment for several years, but stronger trading momentum is starting to appear. An easily covered and safety-minded 6% dividend yield is very attractive today. Undervaluation arguments to own shares also exist. PFE sto...

2024-05-14 11:24:32 ET More on BioNTech, Moderna, etc. BioNTech SE 2024 Q1 - Results - Earnings Call Presentation BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks Moderna announces del...

2024-05-14 05:11:00 ET Shares of the struggling vaccine developer Novavax (NASDAQ: NVAX) bounded 98.7% higher on Friday, May 10. The market was responding to terrific news from Sanofi (NASDAQ: SNY) , a global pharmaceutical giant that wants to market Novavax's COVID-19 a...

2024-05-13 13:53:13 ET More on AstraZeneca, Pfizer Pfizer's Bottom May Be Here - Its Rich Yield Is Tempting Pfizer: A 6% Yield And At 10-Year Lows Pfizer Stock: Not A Value Trap, Here's Why Pfizer to settle over 10,000 Zantac-related cancer claims: report ...

2024-05-13 10:09:30 ET More on Sanofi, Fulcrum Sanofi Q1: Wait And See For Now (Downgrade) Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade) Sanofi 2024 Q1 - Results - Earnings Call Presentation Biggest stock movers today: ARM, ZK...

― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourt...

― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ― ― Fulcrum will receive an upfront payment of $80.0 million, and is eligible to receive $975.0 million in potentia...

2024-05-13 05:49:56 ET More on related stocks: Novavax: Sanofi Partnership Revitalizes My Magnum Opus Novavax, Inc. (NVAX) Q1 2024 Earnings Call Transcript Spotlight On The CPI Print, Walmart Earnings, Google Event And Zeekr Buzz Sanofi to invest over €...

2024-05-13 03:29:35 ET More on Sanofi Sanofi Q1: Wait And See For Now (Downgrade) Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade) Sanofi 2024 Q1 - Results - Earnings Call Presentation Novavax surges as Sanofi COVID vaccine deal ...